Comparing the current results to its competitors, Jazz Pharmaceuticals Plc reported Revenue increase in the 2 quarter 2026 by 15.55 % year on year. The sales growth was above Jazz Pharmaceuticals Plc's competitors' average revenue growth of 12.04 %, achieved in the same quarter.
Jazz Pharmaceuticals Plc's Comment on Competition and Industry Peers
The biopharmaceutical industry is characterized by intense competition among products, including existing therapies, current product candidates, and future candidates such as new chemical entities that may offer improved safety, efficacy, or convenience. Competitors range from large global pharmaceutical companies to smaller research-based firms and institutions. The company faces competition from generic drugs, influenced by certain U.S. state laws that permit or require dispensing generic products when available, often leading to reduced net prices for branded products. Specifically, the company competes with generic versions of high-sodium oxybate and new treatments for cataplexy and excessive daytime sleepiness (EDS) that affect the market for its products Xywav and Xyrem. The company has entered into settlement agreements with ANDA filers concerning these generic competitors.
Overall company sales advanced by 15.55 % Jazz Pharmaceuticals Plc outperformed its competitors in this segment and improved market share, to approx. 0.78 %. << More on JAZZ Market Share.
*Market share is calculated based on total revenue.
Dianthus Therapeutics Inc is a biotechnology company that focuses on developing novel genetic medicines for patients suffering from rare genetic diseases. Their business model revolves around leveraging cutting-edge gene therapy technologies to design and deliver innovative treatments. By partnering with academic institutions and utilizing a proprietary gene therapy platform, they aim to address unmet medical needs and provide potential new therapies for patients with genetic disorders.
Biohaven Ltd operates as a pharmaceutical company that focuses on discovering and developing therapies for neurological diseases and rare disorders. Their business model revolves around conducting extensive research and clinical trials to bring innovative treatments to market. By collaborating with healthcare professionals, regulatory agencies, and investors, Biohaven aims to improve the lives of patients suffering from these conditions and provide a significant return on investment for stakeholders.
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Sources:
Jazz Pharmaceuticals Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Jazz Pharmaceuticals Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
